Evolution of CAR T-cell immunotherapy in terms of patenting activity

Nat Biotechnol. 2019 Apr;37(4):370-375. doi: 10.1038/s41587-019-0083-5.

Authors

Björn Jürgens¹, Nigel S Clarke²

Affiliations

¹ CITPIA PATLIB Center, Agency for Innovation and Development of Andalusia, Seville, Spain.
² European Patent Office, Vienna, Austria. nclarke@epo.org.

PMID: 30940940
DOI: 10.1038/s41587-019-0083-5

No abstract available

MeSH terms

Biotechnology / legislation & jurisprudence
Biotechnology / statistics & numerical data
Biotechnology / trends
Cellular Reprogramming Techniques / statistics & numerical data
Cellular Reprogramming Techniques / trends
Humans
Immunotherapy, Adoptive / legislation & jurisprudence*
Immunotherapy, Adoptive / statistics & numerical data
Immunotherapy, Adoptive / trends
Patents as Topic* / statistics & numerical data
Receptors, Chimeric Antigen / genetics*
T-Lymphocytes / immunology*

Substances

Receptors, Chimeric Antigen